Key Highlights

  • Hyperliquid Strategies closed down 8.80% at $12.85, materially steeper than the peer median loss of 1.1%.
  • The stock finished near the bottom of its session range after opening unchanged.
  • PURR remains up 278.3% year to date despite the session's decline, with a 12% short position representing 1.1 days of average Volume to cover.

Hyperliquid Strategies (NASDAQ:PURR) closed down 8.80% at $12.85, with the decline exceeding the peer median loss of 1.1%. The company-specific selloff matters because it followed a 278.3% year-to-date gain, leaving investors weighing strong momentum against elevated valuation measures and a close near the session low.

Decline Outpaces Peer Group

The decline was materially steeper than the peer median loss of 1.1%, making the weakness specific to the stock rather than a broad sector reaction. Denali Therapeutics fell 1.8%, Arcutis Biotherapeutics declined 1.1%, and Arcus Biosciences slipped 0.9%, showing that PURR absorbed considerably more selling pressure than the selected peers during the same session.

Volume Trails Full-Session Norm

Trading volume indicated meaningful participation, but had not reached the stock's normal full-day activity. A close near the bottom of the daily range also matters because it shows the stock did not recover materially from its intraday weakness. The stock's market Capitalization stood at $3.2 billion, making the dollar move material in absolute terms even as trading volume stayed below its typical full-session level.

RSI Leaves Resistance as the Next Test

PURR remained above its 20-day Moving Average of $12.40, its 50-day average of $9.55, and its 200-day average of $6.76. The 14-day RSI was 57.9, a middle-to-firm reading. MACD at 1.10 sat just above its 1.09 signal line. ADX was 43.5. The nearest technical support was $7.57, followed by $2.88, while resistance stood at $15.54 and then $18.82.

PURR's Valuation Meets a Small Revenue Base

The stock carried a trailing P/E of 20.0, a price-to-sales ratio of 295.5, and a Price-to-Book Ratio of 1.4. Trailing-twelve-month revenue was $9.46 million. Short interest stood at 12% of shares outstanding, with 1.1 days of average volume needed to cover and the position down 14% from the prior settlement.

Peers Moving on This News